Tumor evasion of the immune system by converting CD4+CD25 - T cells into CD4+CD25+ T regulatory cells: Role of tumor-derived TGF-β

Journal of Immunology

Volumn 178, Issue 5, 2007, Pages 2883-2892

  Liu, Victoria C ^a   Wong, Larry Y ^a   Jang, Thomas ^a   Shah, Ali H ^a   Park, Irwin ^a   Yang, Ximing ^a   Zhang, Qiang ^a   Lonning, Scott ^b   Teicher, Beverly A ^b   Lee, Chung ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Genzyme   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IRRADIATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNOLOGY; TUMOR VOLUME;

EID: 33847337912     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.5.2883     Document Type: Article

References (54)

1. Burnet, F. M. 1970. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13: 1-27.
2. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
3. Rosenberg, S. A. 2001. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250: 462-475.
4. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86: 1159-1166.
5. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183: 725-729.
6. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
7. Zhang, L., J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med 348: 203-213.
8. Clemente, C. G., M. C. Mihm, Jr., R. Bufalino, S. Zurrida, P. Collini, and N. Cascinelli. 1996. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77: 1303-1310.
9. Clark, W. H., Jr., D. E. Elder, D. Guerry IV, L. E. Braitman, B. J. Trock, D. Schultz, M. Synnestvedt, and A. C. Halpern. 1989. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81: 1893-1904.
10. + T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61: 5132-5136.
11. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
12. + T cell infiltrations within esophageal carcinomas. Cancer Res. 61: 3932-3936.
13. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099.
14. Marshall, N. A., L. E. Christie, L. R. Munro, D. J. Culligan, P. W. Johnston, R. N. Barker, and M. A. Vickers. 2004. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103: 1755-1762.
15. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761.
16. + T cells. J. Autoimmun. 16: 115-123.
17. - thymocytes. J. Exp. Med. 189: 279-288.
18. Asseman, C., S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie. 1999. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190: 995-1004.
19. + T cells. Proc. Natl. Acad. Sci. USA 99: 8832-8837.
20. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3: 135-142.
21. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192: 295-302.
22. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
23. Asano, M., M. Toda, N. Sakaguchi, and S. Sakaguchi. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184: 387-396.
24. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164.
25. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218.
26. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32: 3267-3275.
27. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25: 207-217.
28. + regulatory T cells. Immunology 109: 319-325.
29. Bluestone, J. A., and A. K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3: 253-257.
30. Woo, E. Y., H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll, J. L. Riley, L. R. Kaiser, and C. H. June. 2002. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168: 4272-4276.
31. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772.
32. Ormandy, L. A., T. Hillemann, H. Wedemeyer, M. P. Manns, T. F. Greten, and F. Korangy. 2005. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65: 2457-2464.
33. Wolf, A. M., D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein. 2003. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9: 606-612.
34. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162: 5317-5326.
35. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886.
36. - precursors. J. Immunol. 169: 4183-4189.
37. - lymphocytes is thymus and proliferation independent. Cancer Res. 66: 4488-4495.
38. + regulatory T cell proliferation. J. Exp. Med. 202: 919-929.
39. Zou, W. 2006. Regulatory T cells, tumor immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
40. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194: 629-644.
41. Chen, T. C., D. R. Hinton, V. W. Yong, and F. M. Hofman. 1997. TGF-B2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells. J. Neuroimmunol. 73: 155-161.
42. Kong, F. M., M. K. Washington, R. L. Jirtle, and M. S. Anscher. 1996. Plasma transforming growth factor-β1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 16: 47-59.
43. Xu, J., A. Ahmad, J. F. Jones, R. Dolcetti, E. Vaccher, U. Prasad, and J. Menezes. 2000. Elevated serum transforming growth factor β1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM. J. Virol. 74: 2443-2446.
44. Dasch, J. R., D. R. Pace, W. Waegell, D. Inenaga, and L. Ellingsworth. 1989. Monoclonal antibodies recognizing transforming growth factor-β: bioactivity neutralization and transforming growth factor β2 affinity purification. J. Immunol. 142: 1536-1541.
45. Danielpour, D. 1999. Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-β. J. Cell Sci. 112: 169-179.
46. Letterio, J. J., and A. B. Roberts. 1998. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16: 137-161.
47. + T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61: 8643-8646.
48. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2: 1.
49. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198: 235-247.
50. Wing, K., Z. Fehervari, and S. Sakaguchi. 2006. Emerging possibilities in the development and function of regulatory T cells. Int. Immunol. 18: 991-1000.
51. Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and H. von Boehmer. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6: 1219-1227.
52. Thomas, D. A., and J. Massague. 2005. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cells 8: 369-380.
53. Gershon, R. K., and K. Kondo. 1970. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18: 723-737.
54. Gershon, R. K., and K. Kondo. 1971. Infectious immunobgical tolerance. Immunology 21: 903-914.